Artelo Biosciences Enters $16.3B Glaucoma Market via Fully Funded Trial
Artelo Biosciences expanded its lead molecule ART27.13 into the $16.3 billion glaucoma market via a fully funded investigator-sponsored trial while advancing three clinical-stage programs in oncology support, neuropathic pain and CNS disorders. ART27.13’s Phase 2 data showed a 6.4% weight gain versus a 5.4% weight loss in cancer anorexia cachexia.
1. Glaucoma Expansion
Artelo Biosciences has launched an investigator-sponsored study of ART27.13 targeting primary open-angle glaucoma, accessing the $16.3 billion ophthalmology market at zero direct cost to shareholders. The trial will evaluate intraocular pressure modulation and neuroprotective effects driven by CB2 receptor activity, with Artelo retaining full data rights.
2. Multi-Platform Pipeline
Beyond ART27.13, the company is running two additional clinical-stage programs: ART26.12, a FABP5 inhibitor in development for chemotherapy-induced peripheral neuropathy with first-in-human safety data complete and Phase 2 enrollment planned for Q3 2026; and ART12.11, a CBD cocrystal with improved bioavailability and MHRA guidance for streamlined Phase 1 trials.
3. Phase 2 Weight Gain Data
In a Phase 2 study of ART27.13 for cancer anorexia cachexia, patients achieved a 6.4% average weight gain compared to a 5.4% loss in the placebo arm, demonstrating a clinically meaningful benefit. This result, combined with European patents to 2041 and unsolicited partnership inquiries, supports broader therapeutic potential.